Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (11)

Advertisement

Free access | 10.1172/JCI110678

Familial Hypercholesterolemia: EVIDENCE FOR A NEWLY RECOGNIZED MUTATION DETERMINING INCREASED FIBROBLAST RECEPTOR AFFINITY BUT DECREASED CAPACITY FOR LOW DENSITY LIPOPROTEIN IN TWO SIBLINGS

Richard E. Ostlund Jr., Richard A. Levy, Joseph L. Witztum, and Gustav Schonfeld

Metabolism Division and Lipid Research Center, Washington University, St. Louis, Missouri 63110

Department of Medicine, Washington University, St. Louis, Missouri 63110

Department of Preventive Medicine, Washington University, St. Louis, Missouri 63110

Find articles by Ostlund, R. in: PubMed | Google Scholar

Metabolism Division and Lipid Research Center, Washington University, St. Louis, Missouri 63110

Department of Medicine, Washington University, St. Louis, Missouri 63110

Department of Preventive Medicine, Washington University, St. Louis, Missouri 63110

Find articles by Levy, R. in: PubMed | Google Scholar

Metabolism Division and Lipid Research Center, Washington University, St. Louis, Missouri 63110

Department of Medicine, Washington University, St. Louis, Missouri 63110

Department of Preventive Medicine, Washington University, St. Louis, Missouri 63110

Find articles by Witztum, J. in: PubMed | Google Scholar

Metabolism Division and Lipid Research Center, Washington University, St. Louis, Missouri 63110

Department of Medicine, Washington University, St. Louis, Missouri 63110

Department of Preventive Medicine, Washington University, St. Louis, Missouri 63110

Find articles by Schonfeld, G. in: PubMed | Google Scholar

Published October 1, 1982 - More info

Published in Volume 70, Issue 4 on October 1, 1982
J Clin Invest. 1982;70(4):823–831. https://doi.org/10.1172/JCI110678.
© 1982 The American Society for Clinical Investigation
Published October 1, 1982 - Version history
View PDF
Abstract

Cultured skin fibroblasts were obtained from two siblings with classic clinical features of homozygous familial hypercholesterolemia. Plasma cholesterol values were 970 and 802 mg/100 ml in the siblings, 332 mg/100 ml in the mother, and 426 mg/100 ml in the father. Fibroblast receptor-specific capacity for binding and degradation of 125I-low density lipoprotein (LDL) at 37°C was 11% of normal, consistent with the diagnosis of “homozygous LDL receptor-defective” hypercholesterolemia, a disorder in which LDL binding activity is low but detectable.

The residual LDL receptor activity was clearly qualitatively abnormal. The Michaelis constant (Km) for 125I-LDL was reduced to 20-40% of normal, indicating a substantially increased affinity for LDL. Increased affinity and reduced capacity for 125I-LDL are also found when normal fibroblasts are assayed at 4°C. As the temperature is raised to 37°C surface LDL binding affinity decreases while capacity increases. At 4°C the fibroblasts of our subjects had an affinity for LDL indistinguishable from normal cells assayed at that temperature and a binding capacity 23% of normal. However, only small changes in affinity and capacity occurred upon increasing the temperature to 37°C. When 125I-apoprotein E-phospholipid vesicles were bound at 37°C the receptor deficiency appeared only half as severe as when 125I-LDL was used as ligand.

A family study suggests that the siblings are genetic compounds rather than homozygotes, having inherited a mutant maternal gene causing absent or silent LDL receptors and a mutant paternal gene resulting in qualitatively altered LDL receptors. It is not clear whether these defects are present at the same or different genetic loci. The altered receptors are characterized by increased affinity and moderately reduced capacity for LDL at 37°C and are accompanied by hypercholesterolemia at least as severe as that associated with familial hypercholesterolemia with absent or nonfunctional LDL receptors.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 823
page 823
icon of scanned page 824
page 824
icon of scanned page 825
page 825
icon of scanned page 826
page 826
icon of scanned page 827
page 827
icon of scanned page 828
page 828
icon of scanned page 829
page 829
icon of scanned page 830
page 830
icon of scanned page 831
page 831
Version history
  • Version 1 (October 1, 1982): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (11)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts